Skip to main content
Brief Communications
August 8, 2000

Retrospective analysis of the use of cyclosporine in myasthenia gravis

August 8, 2000 issue
55 (3) 448-450


Article abstract The authors reviewed the records of patients with myasthenia gravis who took cyclosporine for at least 6 months between November 1987 and January 1999. Of 57 patients who took cyclosporine for an average of 3.5 years, 55 (96%) had clinical improvement. The median time to best clinical response was 7 months. Corticosteroids were discontinued or decreased in 95% of 38 patients taking them. Major side effects included elevated serum creatinine (28%) and malignancy (11%). Five percent could not afford or tolerate the drug.

Get full access to this article

View all available purchase options and get full access to this article.


Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719–724.
Nyberg-Hansen R, Gjerstad L. Myasthenia gravis treated with cyclosporine. Acta Neurol Scand 1988;77:307–313.
Goulon M, Elkharrat D, Lokiec F, Gajdos PH. Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis. Transplant Proc 1988;20 (suppl 4):211–217.
Antonini G, Bove R, Filippini C, Millefiorini M. Results of an open trial of cyclosporine in a group of steroid dependent myasthenic subjects. Clin Neurol Neurosurg 1990;92:317–321.
Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 1997;244:542–547.
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Inc. Myasthenia gravis: recommendations for clinical research standards. Neurology 2000 (in press).
Sanders DB, Howard JF. Jr. Single-fiber electromyography in myasthenia gravis. Muscle Nerve 1986;9:809–819.
Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530–534.

Information & Authors


Published In

Volume 55Number 3August 8, 2000
Pages: 448-450
PubMed: 10932288

Publication History

Received: December 2, 1999
Accepted: April 6, 2000
Published online: August 8, 2000
Published in print: August 8, 2000


Request permissions for this article.


Affiliations & Disclosures

Emma Ciafaloni, MD
From the Department of MedicineDivision of Neurology, Duke University Medical Center, Durham, NC.
Nirjaleshwar K. Nikhar, MD, MRCP
From the Department of MedicineDivision of Neurology, Duke University Medical Center, Durham, NC.
Janice M. Massey, MD
From the Department of MedicineDivision of Neurology, Duke University Medical Center, Durham, NC.
Donald B. Sanders, MD
From the Department of MedicineDivision of Neurology, Duke University Medical Center, Durham, NC.


Address correspondence and reprint requests to Dr. Donald B. Sanders, Duke University Medical Center, DUMC 3403, Durham, NC 27710.

Metrics & Citations



Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Unlocking the Complexity of Neuromuscular Diseases: Insights from Human Pluripotent Stem Cell-Derived Neuromuscular Junctions, International Journal of Molecular Sciences, 24, 20, (15291), (2023).
  2. Trastornos de la unión neuromuscular: miastenia gravis, Medicine - Programa de Formación Médica Continuada Acreditado, 13, 77, (4574-4584), (2023).
  3. Ocular Myasthenia Gravis, Current Treatment Options in Neurology, 25, 6, (151-167), (2023).
  4. Treatment of acquired autoimmune myasthenia gravis: Where are we today?, Galenika Medical Journal, 1, 2, (44-51), (2022).
  5. Current Treatment of Myasthenia Gravis, Journal of Clinical Medicine, 11, 6, (1597), (2022).
  6. Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort, Therapeutic Advances in Chronic Disease, 13, (204062232211225), (2022).
  7. Myasthenia Gravis and Thymectomy, Journal of Cardiac Critical Care TSS, 05, 03, (229-237), (2022).
  8. Current and Upcoming Treatment Modalities in Myasthenia Gravis, Journal of Clinical Neuromuscular Disease, 23, 2, (75-99), (2021).
  9. Update in immunosuppressive therapy of myasthenia gravis, Autoimmunity Reviews, 20, 1, (102712), (2021).
  10. Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders, Pharmacology of Immunosuppression, (245-265), (2021).
  11. See more

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text HTML

View Full Text HTML







Share article link